CRISPR Therapeutics AG (CRSP) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, CRISPR Therapeutics AG (NASDAQ: CRSP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $49.99 (-2.78% 1D, market cap $4.83B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRSP ranks #587 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRSP carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.6%. By comparison, SRRK (Scholar Rock Holding Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $5.23B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, CRSP leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per CRSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674416), CRISPR Therapeutics AG generated $3.5M in revenue (-90.6% YoY), -$581.6M in net income, and -$345.9M in free cash flow against $2.27B in total assets and $154.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 7.97 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
20D Institutional Volume Accumulation (±8.9% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CRSP currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($53.65) and Max Pain ($52.49) forces dealer call-delta covering toward $66.62.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
CRISPR Therapeutics AG (CRSP) dropped -2.78% to $49.99, trading at 30% of its 52-week range ($44.12 – $63.45). Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately.
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -90.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, CRISPR Therapeutics AG (CRSP) ranks #587 by composite RQD confidence (35/100, grade D-) and #163 by equity capitalization ($4.83B). Within this direct 5-issuer industry benchmark cohort, CRSP leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. ADPT currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with CRSP at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRSP
ACTIVE
CRISPR Therapeutics AG | D- | 35/100 | — | — | -30.6% | -2.78% | $4.83B | Benchmark Subject |
| SRRK Scholar Rock Holding Corporation | D- | 41/100 | — | — | -35.0% | -2.25% | $5.23B | /srrk-vs-crsp → |
| CGON CG Oncology Inc. | D- | 42/100 | — | — | -20.8% | -4.20% | $5.49B | /cgon-vs-crsp → |
| ADPT Adaptive Biotechnologies Corporation | D | 48/100 | — | 74.2% | -12.5% | -5.93% | $4.00B | /adpt-vs-crsp → |
| IMVT Immunovant Inc. | D- | 37/100 | — | — | -35.0% | -2.60% | $5.87B | /imvt-vs-crsp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CRISPR Therapeutics AG (CRSP) reported GAAP revenue of $3.5M (-90.6% vs. FY2024 revenue of $37.3M , and -99.1% cumulative change since FY2023) , GAAP net income of -$581.6M, operating cash flow of -$345.0M, and free cash flow of -$345.9M (-139.1% YoY). On the balance sheet, CRSP closed FY2025 with $2.27B in total assets against $154.5M in total debt (Altman Z-Score: 7.97, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.5M | -$581.6M | -$345.0M | -$345.9M | $2.27B | $154.5M |
| FY2024 (FY) | 2024-12-31 | $37.3M | -$366.3M | -$142.8M | -$144.7M | $2.24B | $139.5M |
| FY2023 (FY) | 2023-12-31 | $371.2M | -$153.6M | -$260.4M | -$277.1M | $2.89B | $675.2M |
As of 2026-11-03, CRISPR Therapeutics AG (NASDAQ: CRSP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $49.99 (-2.78% 1D, market cap $4.83B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CRSP ranks #587 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRSP carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.6%. By comparison, SRRK (Scholar Rock Holding Corporation) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $5.23B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, CRSP leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per CRSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674416), CRISPR Therapeutics AG generated $3.5M in revenue (-90.6% YoY), -$581.6M in net income, and -$345.9M in free cash flow against $2.27B in total assets and $154.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CRSP last traded at $49.99 (-2.78% on volume of 1,025,957 shares), positioning the stock -6.82% below its 50-day simple moving average ($53.65) and -5.43% below its 200-day simple moving average ($52.86). Across its 52-week range of $44.12 to $63.45, CRSP sits at the 30.4% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($45.54 to $54.44).
CRISPR Therapeutics AG (CRSP) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $49.99 (-2.78% 1D, market capitalization $4.83B).
CRISPR Therapeutics AG is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. It has a market capitalization of $5.2B. Products, customer segments, and revenue mechanics beyond the sector and industry classification are not detailed in the source data. Reported revenue has declined across the three periods provided, .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CRISPR Therapeutics AG (CRSP) reported $3.5M in annual revenue (up from $37.3M in FY2024, -90.6% YoY) and -$581.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($371.2M revenue, -$153.6M net income) through FY2025, CRSP scaled operating cash flow to -$345.0M and free cash flow to -$345.9M, backed by $2.27B in total assets against $154.5M in total debt.
For an investor, the key second-order question is whether clinical catalysts in the news wire translate into revenue, but the sources do not establish that linkage.
Real-time company headlines, analyst actions, and sector developments for CRISPR Therapeutics AG (CRSP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering CRISPR Therapeutics AG (CRSP) market action, institutional positioning, and fundamental catalysts.
The balance sheet shows an Altman Z of 7.97 and Debt/Equity of 0.08 alongside cash of $347.6M above debt of $154.5M, giving the company a sizable cushion against near-term solvency stress.. When you look under the hood at CRSP, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -30.6% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $63.45. My 12M target is $62.22.
@MacroHawk_NYC Agree on the RQD 35/100 quality, though with 1.12 beta I'm scaling in with half-size at $51.42 and keeping dry powder in case we test $47.82.
Fading this rally in CRSP at $51.42. Reported revenue collapsed from $371.2M in FY 2023 to $3.5M in FY 2025 while ROIC sits at -30.6% and FCF yield at -6.59%, with the RQD rating assigning a Roarable Sell grade.. With a beta of 1.12 and the stock sitting at $51.42 (52-wk range $44.12–$63.45), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: